By Oceans Marasha The decision by Moderna to halt plans for a vaccine production facility in Kenya has sparked widespread concern among healthcare stakeholders in Africa, highlighting ongoing challenges in vaccine accessibility and local production capacity. Despite setbacks, experts believe these challenges are surmountable with strategic efforts and collaboration. Michael Mynhardt, CEO at MMH & Partners Africa, expressed frustration over Moderna 's decision, emphasising the continent’s historical dependence on external entities for health solutions.
He noted that while Africa often receives pledges of support, tangible actions for sustainable health security are limited. The urgency to establish local vaccine manufacturing capabilities in Africa stems not only from the immediate need for Covid-19 vaccines but also from long-standing health crises and vulnerabilities across the continent. Mynhardt acknowledged the risks involved in such ventures but emphasised they are not insurmountable with proper planning and commitment.
He cautioned against overly sensationalised reactions to Moderna's withdrawal, urging stakeholders to recognise the complexities and economic realities involved. He stressed the importance of securing commitments from governments and buyers to ensure the sustainability of vaccine production ventures. De-risking vaccine production requires trust and commitment from all stakeholders, particularly governments and international organisations.
The recent col.
